Table 2. Multivariable Cox hazard model in relation to OS.
Variables | Original cohort | PS-matching cohort | |||||
---|---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | ||
Age (yr) | |||||||
≤55 | Reference | 0.464 | Reference | 0.194 | |||
>55 | 0.835 | 0.514–1.350 | 0.664 | 0.355–1.228 | |||
Surgery | |||||||
Group I | Reference | 0.538 | Reference | 0.615 | |||
Group II | 0.846 | 0.703–2.064 | 1.170 | 0.633–2.187 | |||
FIGO stage | |||||||
II | Reference | 0.035 | Reference | 0.674 | |||
III–IV | 1.706 | 1.044–2.854 | 1.142 | 0.616–2.167 | |||
CA125 value (U/mL) | |||||||
≤35 | Reference | 0.168 | Reference | 0.175 | |||
>35 | 1.577 | 0.834–3.304 | 1.761 | 0.792–4.673 | |||
Chemotherapy | |||||||
Non-TP | Reference | 0.497 | Reference | 0.242 | |||
TP | 0.832 | 0.500–1.433 | 0.672 | 0.357–1.325 |
Group I is patients with full-staging standard surgery and group II is patients with non-staging limited surgery.
CA125, cancer antigen 125; CI, confidence interval; HR, hazard ratio; FIGO, Internatinal Federation of Gynecology and Obstetrics; OS, overall survival; PS, propensity score; TP, taxane plus platinum.